Vanguard Global Advisers
CLYM

Vanguard Global Advisers’s Climb Bio CLYM Stock Holding History

Vanguard Global Advisers’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$131K Hold
10,061
– – ﹤0.01% 2674
2026
Q1 		$68.9K Buy
+10,061
New +$58K ﹤0.01% 2877

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Global Advisers's CLYM Position: Q2 2026 in Review

Vanguard Global Advisers held its Climb Bio (CLYM) position steady in Q2 2026 at 10,061 shares worth $131K. The position accounts for ﹤0.01% of the portfolio, ranked #2674.

Vanguard Global Advisers first reported a position in CLYM in Q1 2026 and has held it in 2 quarters since. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Vanguard Global Advisers held 10,061 shares of Climb Bio worth $131K as of Q2 2026.
  • Vanguard Global Advisers left its Climb Bio share count unchanged in Q2 2026.
  • Climb Bio made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2674 holding.
  • Vanguard Global Advisers first reported a position in Climb Bio in Q1 2026 and has held it in 2 quarters since.
  • 109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.